EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains

Kopplung von CZE, Flüssigphasen-Ionenmobilität und MS/MS für quantitative Top-Down-Proteomik: deutliche Proteoform-Unterschiede zwischen gesunden und Alzheimer-Gehirnen

Mehrdad Falamarzi Askarani, Fei Fang, Scott E Counts, Liangliang Sun iD

PROTEOMICS · 2026-04 · 26 (4) · 23-35

DOI: 10.1002/pmic.70041 ↗

Auf einen Blick

In postmortalen Kortexproben von AD-Fällen und Kontrollen wurden proteomische Unterschiede untersucht. Es zeigte sich eine starke Veränderung des Proteoform-Profils bei Alzheimer.

Fragestellung

Unterscheiden sich Proteoform-Profile im Kortex von AD-Patient:innen und gesunden Kontrollen bei quantitativer Top-Down-Proteomik?

Methode

Quantitative Top-Down-Proteomik mit CZE gekoppelt an MS/MS an postmortalen Kortexproben von AD-Fällen und Kontrollen.

Ergebnisse

3191 einzigartige Proteoformen wurden identifiziert. Über 2200 Proteoformen fanden sich nur in AD- oder nur in Kontrollproben; 157 zeigten signifikante Mengenunterschiede zwischen beiden Gruppen.

Schlussfolgerung der Autor:innen

Die Studie zeigt eine tiefgehende Veränderung des Proteoform-Profils im AD-Gehirn und nennt potenzielle neue Proteoform-Biomarker für Diagnose und Therapieentwicklung.

Kernaussagen

  • 3191 einzigartige Proteoformen wurden identifiziert
  • Über 2200 Proteoformen nur in einer der beiden Gruppen
  • 157 gemeinsame Proteoformen mit signifikanten Mengenunterschieden

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift PROTEOMICS, online erschienen am 14.09.2025. Verfasst von Mehrdad Falamarzi Askarani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Michigan State University, East Lansing, Michigan, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Proteomics, Tandem Mass Spectrometry, Brain. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute in Aging Grant, NIGMS NIH HHS, National Institute of General Medical Sciences (NIGMS).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and pathological protein aggregation. Comprehensive quantitative proteomics of brain tissues from AD patients is critical for pursuing a better understanding of the molecular mechanisms that drive AD progression. Here, we present one of the first quantitative top‐down proteomics (TDP) studies of postmortem cortex samples from AD patients and healthy controls to profile their proteoform differences by coupling capillary zone electrophoresis (CZE, liquid‐phase ion mobility) to tandem mass spectrometry (MS/MS). We identified 3191 unique proteoforms and uncovered a drastic transformation in the proteoform profile in AD compared to healthy controls. Over 2200 proteoforms were exclusively identified in either AD or healthy control samples, and 157 proteoforms identified in both AD and control samples showed statistically significant abundance differences between the two conditions. Gene Ontology and pathway analysis of the genes associated with those proteoforms revealed broad changes in biological processes in AD brains, for example, telomere organization, substantia nigra development, amyloid fibril formation, microtubule cytoskeleton organization, progressive neurological disorders, long‐term synaptic potentiation, and axogenesis. These biological processes are highly associated with the development of AD. Our study revealed a pool of potential novel proteoform biomarkers of AD in human brain samples for early diagnosis and therapy development. Summary Alzheimer's disease (AD) is a chronic neurodegenerative disease, destroying brain cells and causing thinking ability and memory to decline over time. Proteins (e.g., amyloid and tau) play key roles in the development of AD. Global and accurate protein measurement of human brains of AD patients and healthy controls will shed new light on the molecular mechanisms driving AD progression and discover new biomarkers for AD diagnosis and therapeutic development. Here, we performed the first CZE‐MS/MS‐based quantitative top‐down proteomics (TDP) of a small cohort of AD human brain samples and healthy controls (5 AD and 5 control) to determine the differentially quantified proteoforms between the two health conditions. Over 3000 proteoforms were identified, and only about 700 proteoforms were detected in both conditions, indicating drastically different proteoform profiles between the two conditions. The differentially quantified proteoforms (e.g., tau, neurogranin, and calmodulin‐1 proteoforms) are associated with biological processes relevant to AD development, for example, amyloid fibril formation, microtubule disruption, synaptic transmission, and axogenesis. The results offer a deep view of the proteoform transformation in the AD human brain compared to the healthy control, providing potential proteoform biomarkers for AD diagnosis and proteoform targets for therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseProteomicsTandem Mass SpectrometryBrainProteomeHumansMaleElectrophoresis, CapillaryFemaleAgedAged, 80 and overCase-Control Studies

Stichwörter der Autor:innen

Alzheimer's diseaseCZE‐MS/MShuman brainproteoformtau phosphorylationtop‐down proteomics

Substanzen

Proteome

Autor:innen und Institutionen

  • Department of Chemistry, Michigan State University, East Lansing, Michigan, USA.
  • Department of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.

ORCID-Profile: Liangliang Sun

Förderung

  • National Institute in Aging Grant
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences (NIGMS)
  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Falamarzi Askarani, M., Fang, F., Counts, S. E., & Sun, L. (2026). Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains. PROTEOMICS, 26(4), 23-35. https://doi.org/10.1002/pmic.70041

Vancouver

Falamarzi Askarani M, Fang F, Counts SE, Sun L. Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains. PROTEOMICS. 2026;26(4):23-35. doi:10.1002/pmic.70041

BibTeX
@article{FalamarziAskarani2026,
  author = {Falamarzi Askarani, Mehrdad and Fang, Fei and Counts, Scott E and Sun, Liangliang},
  title = {Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains},
  journal = {PROTEOMICS},
  year = {2026},
  volume = {26},
  number = {4},
  pages = {23--35},
  doi = {10.1002/pmic.70041}
}
Kostenlos starten →